Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer
January 15, 2021 at 05:15 pm
Share
On January 14, 2021, Richard C. Woodman, MD, Senior Vice President, Chief Medical Officer of Onconova Therapeutics, Inc., resigned from the Company effective January 15, 2021 to assume a position with another company. The Company wishes Dr. Woodman well, waived the notice period required under his employment agreement, and thanked Dr. Woodman for his scientific contributions and leadership setting the foundation with the Company’s President, CEO and former Chief Medical Officer Steven M. Fruchtman, MD for the ongoing research and development of the Company’s compounds.
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).